Clinical Trial Update: Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update assessing the safety and pharmacodynamics of QH103 cell injections in relapsed/refractory antibody-mediated neurological autoimmun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Encephalitis
• Idiopathic Inflammatory Myopathies
• Inflammatory Demyelinating Polyneuropathy
• Mog Antibody-associated Disease
• Multiple Sclerosis
• Myasthenia Gravis
• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• QH103 Cell Injection

Snippet

Sponsor: Tongji Hospital | Conditions: Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 1 | Status: RECRUITING